📰 ReutersReutersCodex · 实盘不做把握 5/10
北京时间·🕒 发布 19:17:36时区推断·⟳ 抓取 19:21:54·⚡ 决策 07-27 19:23:38 +1m44s·91.9 天前
诺诚健华口服银屑病药物III期达到主要终点
Reuters报道诺诚健华实验性口服TYK2/JAK通路银屑病药物III期达到主要终点，方向上利好公司自免管线。
📄 原文Reuters↗ 原文
Chinese drugmaker Innocare Pharma (688428.SS) said on Monday one of its experimental oral treatments for moderate-to-s…
不做 诺诚健华（688428.SH）
事件方向利好但不是低预期差首发；同一TYK2皮肤科管线7月中旬已连续披露并被交易，688428.SH已有放量高波动和回撤，本条缺少完整疗效/申报地区/商业化量级，A股盘后明牌不追。
不做 诺诚健华（09969.HK）
港股同为直接受益标的，但事件到达时已收盘且同一管线预期已被前序公告抬高；09969.HK最新可见价格仍在前序催化后回落，次日高开追入的正期望不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司2025年报业务更新已披露ICP-488银屑病III期接近完成入组，并强调TYK2皮肤科管线是2026年重要数据催化。
- 公司公告Soficitinib治疗中重度特应性皮炎III期达到主要终点，开启7月TYK2管线读数密集扩散。市场反应:688428.SH在7月15日至17日出现放量高波动，7月17日收跌约9%。
- 公司公告Soficitinib白癜风II/III适应性研究II期部分达到主要终点，进一步提高同一管线预期。市场反应:09969.HK相关新闻在7月16日后已被财经终端转载。
- Reuters报道诺诚健华口服银屑病药物后期试验达到主要目标，并称公司计划在完成III期研究后推进监管申报。市场反应:事件到达时A股和港股均已收盘，尚无本地连续交易反应。
关键理由
- Reuters报道诺诚健华实验性口服TYK2/JAK通路银屑病药物III期达到主要终点，方向上利好公司自免管线。
- 公司2025年收入约23.75亿元、已首次盈利，皮肤科自免管线具长期期权价值，但本条未披露具体PASI数据、监管申报地区和上市时间。
- 同一TYK2管线AD/白癜风积极读数已在7月15日至16日密集披露，688428.SH随后出现高开低走和大幅回撤，本次Reuters跟进的短线新鲜度和可追空间不足。
主要风险
- 若公司随后在港交所/上交所正式公告披露强于竞品的完整III期疗效和明确NDA时间表，需由新信号重新评估。
- A/H股均已收盘，次日若直接高开，明牌临床读数容易出现见光死。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-07-15 · 影响 weakens
同一TYK2皮肤科管线AD/白癜风读数已在7月15日至16日披露并扩散，随后A股出现放量下跌，削弱追多胜率。
检索:诺诚健华 TYK2 7月 临床 主要终点 股价 回撤 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-03-25 · 影响 weakens
公司披露皮肤科市场空间大，但本条Reuters未给出完整疗效数值、申报国家、上市节奏和销售峰值，短线量级难以精确落地。
检索:InnoCare ICP-488 psoriasis Phase III revenue market filing details 原文 ↗
原文全文
展开原文 · 1,302 字
Chinese drugmaker Innocare Pharma (688428.SS) said on Monday one of its experimental oral treatments for moderate-to-severe plaque psoriasis showed a "consistent treatment effect" in a late-stage clinical trial, as it seeks to compete with Western rivals in a growing market.
Plaque psoriasis is a chronic disease that causes red, scaly, inflamed patches on the skin. Data suggests about 8.66 million people in China live with psoriasis and the number there is on the rise, according to Innocare.
Pills like Bristol Myers Squibb's (BMY.N) Sotyktu and Amgen's (AMGN.O) Otezla offer a convenient option to treat plaque psoriasis, in a global market largely dominated by injectables. As well as Innocare, other drugmakers including Takeda Pharmaceutical (4502.T) are developing experimental oral treatments.
"Multiple secondary endpoints were successfully met, demonstrating a consistent treatment effect across efficacy measures," Innocare said in a statement, adding it plans to advance regulatory filing for the drug, fadeucravacitinib, following completion of its Phase III study.
Beijing-based Innocare specializes in drugs for the treatment of cancer and autoimmune diseases. Its statement did not indicate in which countries it planned to seek approval for fadeucravacitinib.
Plaque psoriasis is a chronic disease that causes red, scaly, inflamed patches on the skin. Data suggests about 8.66 million people in China live with psoriasis and the number there is on the rise, according to Innocare.
Pills like Bristol Myers Squibb's (BMY.N) Sotyktu and Amgen's (AMGN.O) Otezla offer a convenient option to treat plaque psoriasis, in a global market largely dominated by injectables. As well as Innocare, other drugmakers including Takeda Pharmaceutical (4502.T) are developing experimental oral treatments.
"Multiple secondary endpoints were successfully met, demonstrating a consistent treatment effect across efficacy measures," Innocare said in a statement, adding it plans to advance regulatory filing for the drug, fadeucravacitinib, following completion of its Phase III study.
Beijing-based Innocare specializes in drugs for the treatment of cancer and autoimmune diseases. Its statement did not indicate in which countries it planned to seek approval for fadeucravacitinib.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。